- Home
- RLAY vs NRIX Comparison
RLAY vs NRIX Comparison
Compare RLAY & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- NRIX
- Stock Information
- Founded
- RLAY 2015
- NRIX 2009
- Country
- RLAY United States
- NRIX United States
- Employees
- RLAY N/A
- NRIX N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- NRIX Health Care
- Exchange
- RLAY Nasdaq
- NRIX Nasdaq
- Market Cap
- RLAY 1.0B
- NRIX 750.4M
- IPO Year
- RLAY 2020
- NRIX 2020
- Fundamental
- Price
- RLAY $6.15
- NRIX $12.28
- Analyst Decision
- RLAY Strong Buy
- NRIX Strong Buy
- Analyst Count
- RLAY 9
- NRIX 14
- Target Price
- RLAY $16.00
- NRIX $26.29
- AVG Volume (30 Days)
- RLAY 2.2M
- NRIX 1.9M
- Earning Date
- RLAY 11-06-2025
- NRIX 10-09-2025
- Dividend Yield
- RLAY N/A
- NRIX N/A
- EPS Growth
- RLAY N/A
- NRIX N/A
- EPS
- RLAY N/A
- NRIX N/A
- Revenue
- RLAY $8,355,000.00
- NRIX $83,687,000.00
- Revenue This Year
- RLAY $27.30
- NRIX $58.48
- Revenue Next Year
- RLAY $7.43
- NRIX N/A
- P/E Ratio
- RLAY N/A
- NRIX N/A
- Revenue Growth
- RLAY N/A
- NRIX 48.32
- 52 Week Low
- RLAY $1.78
- NRIX $8.18
- 52 Week High
- RLAY $7.64
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- RLAY 45.56
- NRIX 60.33
- Support Level
- RLAY $6.64
- NRIX $11.98
- Resistance Level
- RLAY $7.42
- NRIX $13.03
- Average True Range (ATR)
- RLAY 0.44
- NRIX 0.83
- MACD
- RLAY -0.19
- NRIX 0.08
- Stochastic Oscillator
- RLAY 8.31
- NRIX 68.40
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.